MLLT3 and acute myeloid leukemia: For example, RUNX1 is active in both leukemias and FBM, but past work has also shown that RUNX1 expression is higher in KMT2A-AFF1 ALLs than in KMT2A-MLLT3 AML (Wilkinson et al. 2013).